SBIR/STTR Research Award

Treatment and/or Prevention of Urinary Tract Infections

Award identifier a783b41cefd36fd512a8c533e98430a110ea976862263002c36d15323a3852a6Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$226,733

Program and phase

STTR · Phase I

Award year

2008

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
BIOMEDICAL DEVELOPMENT CORP
Proposal award date
Not reported
Contract end date
Not reported
UEI
CATLLUJNR7W4
Solicitation number
PHS2007-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Urinary tract infections (UTIs) are very common bacterial infections that affect millions of people each year. In the U.S., approximately 10% of women are diagnosed with cystitis annually, with an associated cost of 1. 6 billion. UTIs are also the most commonly occurring nosocomial infection, and nosocomial UTIs mostly arise as a consequence of indwelling urinary catheters. Although UTIs are generally effectively treated with antibiotic therapy, the emergence of resistan ce among uropathogens is becoming more common and has developed into one of the most important factors impacting the management of UTIs. The goal of this project is to develop a novel product for the treatment and/or prevention of urinary tract infections that is unlikely to induce microbial resistance. The product has been shown to be safe in previous human studies. Phase I studies will focus on completing federal regulatory requirements including manufacturing the product in a quality system and submittin g an Investigational New Drug application to the FDA. Subsequent to the acceptance of the IND by the FDA, the treatment will be tested in a clinical trial of treatment of acute, uncomplicated UTI. The Specific Aims of the proposal are: Aim 1. Complete Regu latory Requirements for an Investigational New Drug Aim 2. Evaluate Efficacy of the Treatment in a Human Clinical Trial of Cystitis PUBLIC HEALTH RELEVANCE Urinary tract infections (UTIs) are the second most common type of human infection and a ffect millions of people each year. UTIs account for about 7.3 million doctor visits annually. An estimated 1 in 3 women will have at least one UTI requiring antimicrobial treatment by the age of 24. During their lifetimes, more than half of all women will have a urinary infection, and these infections are often recurrent. A new therapy to treat and/or prevent UTIs is needed due to increased microbial resistance to current antibiotic treatments. An agent to prevent and treat UTI that does not encourage micr obial resistance would have a significant impact on public health.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

64 SBIR/STTR records share this UEI (1985–2025). Reported award amounts total $18,429,764. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services, Department of Agriculture

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.